K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value.

ISRN Mol Biol · 2012 · PMC4890888 · PMID 27398239

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

a nonsignificant trendP = 0.17not close (p > 0.1)

Although a nonsignificant trend toward longer survival (9.6 versus 8.3 months HR 0.89, P = 0.17) was reported, the primary end point of improved PFS in the cetuximab arm was not met (4.4 versus 4.2 months, P = 0.2).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.